Valuation: DiaSorin S.p.A.

Market Cap 3.92B 4.46B 3.71B 3.37B 6.32B 428B 6.36B 44.43B 17.16B 219B 16.75B 16.39B 702B P/E 2026 *
22.9x
P/E 2027 * 20.3x
Enterprise Value 4.63B 5.27B 4.38B 3.97B 7.46B 505B 7.5B 52.43B 20.25B 258B 19.77B 19.34B 829B EV / Sales 2026 *
3.75x
EV / Sales 2027 * 3.41x
Free-Float
37.17%
Yield 2026 *
1.64%
Yield 2027 * 1.72%
Manager TitleAgeSince
Chief Executive Officer 60 2007-03-25
Director of Finance/CFO - 2024-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 2016-04-27
Director/Board Member 63 2007-03-25
Chairman 57 2022-04-28
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.45B
+0.06%+2.29%+186.90%+491.65% 23.79B
+3.17%+12.53%+684.92%+115.78% 11.17B
+2.57%+11.31%-29.47%-10.45% 10.42B
-0.72%+3.28%+5.52% - 9.04B
+0.03%-0.59%+96.94%+43.38% 6.51B
+3.94%+1.37%-27.39%-22.39% 5.59B
+0.61%+3.47%+6.93%-6.51% 4.45B
-4.05%-4.73%+53.55%+58.74% 3.86B
+1.43%+6.09%-13.29%-26.52% 2.86B
Average +0.69%+2.98%+107.18%+80.46% 8.63B
Weighted average by Cap. +0.90%+3.27%+161.12%+191.70%

Financials

2026 *2027 *
Net sales 1.23B 1.4B 1.17B 1.06B 1.99B 135B 2B 13.98B 5.4B 68.75B 5.27B 5.16B 221B 1.31B 1.49B 1.24B 1.12B 2.11B 143B 2.12B 14.84B 5.73B 72.98B 5.59B 5.47B 235B
Net income 183M 208M 173M 157M 295M 19.98B 297M 2.07B 800M 10.19B 781M 764M 32.76B 206M 234M 194M 176M 331M 22.44B 333M 2.33B 899M 11.45B 878M 859M 36.8B
Net Debt 707M 803M 668M 606M 1.14B 77.12B 1.14B 8B 3.09B 39.35B 3.02B 2.95B 126B 542M 616M 512M 465M 873M 59.15B 878M 6.14B 2.37B 30.18B 2.31B 2.26B 96.99B
Logo DiaSorin S.p.A.
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
78.80EUR
Average target price
72.81EUR
Spread / Average Target
-7.61%

Quarterly revenue - Rate of surprise